Werkgroep Cardiologische centra Nederland

HORIZON (Recruiting)

A randomized double-blind, placebo-controlled, multicenter study assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease
Medicine
TQJ230
Population
ASCVD
Phase
III
Starting year
2019
More information
Clinicaltrials.gov

Director of Study

dr. B.L.J.H. Kietselaer (Cardioloog)
Sittard-Geleen, Zuyderland Medisch Centrum